U.S. Concrete (USCR) to Sell California Pre-Cast Operations

EULESS, TX — (Marketwire) — 08/03/12 — U.S. Concrete, Inc. (NASDAQ: USCR) announced today that it has executed a definitive asset purchase agreement to sell substantially all of the Company’s California pre-cast operations to Oldcastle Precast, Inc. The Company’s California pre-cast operations consist of Central Precast Concrete, Inc., San Diego Precast Concrete, Inc. and Sierra Precast, Inc., which are also parties to the definitive sales agreement.

U.S. Concrete President and Chief Executive Officer, William J. Sandbrook, said, “We are extremely pleased to have reached this agreement with Oldcastle Precast. This divestiture is a major milestone in the strategic repositioning of our company into the premier, focused domestic supplier of ready-mix concrete in the United States. The proceeds provide us the opportunity to increase cash deployed for earning enhancing activities such as acquisitions, organic growth opportunities and debt repayment.”

This transaction is subject to customary closing conditions and is expected to close during the third quarter of 2012.

For more information on this transaction, please see the Company’s Current Report on Form 8-K filed August 3, 2012, visit http://www.us-concrete.com/sec.asp or contact U.S. Concrete at 817-835-4111 or email lrussell@us-concrete.com.

U.S. Concrete services the construction industry in several major markets in the United States through its two business segments: ready-mixed concrete and concrete-related products; and precast concrete products. As of the date of this press release, the Company has 95 fixed and 12 portable ready-mixed concrete plants, seven precast concrete plants and seven producing aggregates facilities. During 2011, these plant facilities produced approximately 4.0 million cubic yards of ready-mixed concrete from continuing operations and 3 million tons of aggregates. For more information on U.S. Concrete, visit www.us-concrete.com.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This press release contains various forward-looking statements and information that are based on management’s beliefs, as well as assumptions made by and information currently available to management. These forward-looking statements speak only as of the date of this press release. U.S. Concrete disclaims any obligation to update these statements and cautions you not to rely unduly on them. Forward-looking information includes, but is not limited to the effect of the Company’s sale of the California pre-cast operations. Although U.S. Concrete believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that those expectations will prove to have been correct. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the possibility that the anticipated benefits from such activities, events, developments or transactions cannot be fully realized, the possibility that costs or difficulties related thereto will be greater than expected and the possibility that the proposed transaction does not close, including, but not limited to, due to the failure to satisfy the closing conditions. Should one or more of these risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those expected. Additional risks affecting U.S. Concrete are discussed in greater detail in U.S. Concrete’s filings with the Securities and Exchange Commission; including U.S. Concrete’s Annual Report on Form 10-K for the year ended December 31, 2011 and its Form 10-Q for the three months ended March 31, 2012.

Contact:
Kevin Kohutek
VP, Controller
U.S. Concrete, Inc.

International Tower Hill (THM) To Close CAD $24.6M First Tranche of Non-Brokered Private Placement

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 08/03/12 — International Tower Hill Mines Ltd. (TSX:ITH)(NYSE MKT:THM)(NYSE Amex:THM)(FRANKFURT:IW9) (“ITH” or the “Company”) is pleased to announce that it will close the first tranche of its previously announced up to CAD 29.6 million non-brokered private placement financing (the “Offering”) today.

The first tranche of the Offering consists of 9,458,308 common shares of the Company at a price of CAD 2.60 per common share for gross proceeds of CAD 24.6 million. The participants in the first tranche of the Offering include Paulson & Co., Tocqueville Asset Management, LP, AngloGold Ashanti (USA) Exploration Inc., ITH management and insiders as well as other institutional funds.

The second stage of the Offering will involve the issuance of up to CAD 5 million of common shares, at a price per share equal to a 10% discount from the five day volume weighted average price for the common shares as at September 10, 2012, subject to a maximum issuance of 3,000,000 shares. The single placee in the second stage is purchasing CAD 5 million of common shares in the first stage of the Offering and has committed to close the second stage portion of the Offering. Closing of the second stage is anticipated on or before September 21, 2012. The Company will pay a 4% cash finder’s fee in connection with the issuance of up to CAD 10 million of shares to this investor.

All common shares issued in the Offering will be subject to a hold period in Canada of four months from the closing of the first or second stage of the Offering, as applicable. All common shares issued in the United States will be subject to resale restrictions under U.S. federal and state securities laws. Completion of the second stage of the Offering is subject to the Company obtaining all necessary regulatory approvals, including acceptance for filing by the Toronto Stock Exchange.

The Company intends to use the net proceeds of the private placement for the completion of its bankable Feasibility Study and continued project advancement at the Livengood Gold project in Alaska as well as for general working capital purposes.

The common shares issued and to be issued in the Offering have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act”) or any applicable securities laws of any state of the United States and may not be offered or sold in the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) or persons in the United States absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the common shares to be issued in the Offering, nor shall there be any offer or sale of the common shares to be issued in the Offering in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About International Tower Hill Mines Ltd.

International Tower Hill Mines Ltd. controls a 100% interest in the world-class Livengood Gold Project accessible by paved highway 70 miles north of Fairbanks, Alaska.

On behalf of International Tower Hill Mines Ltd.

Jeffrey A. Pontius, Interim Chief Executive Officer

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation. All statements, other than statements of historical fact, included herein, including, without limitation, statements regarding the anticipated completion of the second stage of the Offering and the proposed use of the proceeds of the Offering by the Company, the size and characteristics of, or the discovery and delineation of, mineral deposits, resources or reserves, the potential for the expansion of the estimated resources at the Livengood property, the identification of additional deposits on the Company’s Livengood property, the preparation or completion of a feasibility study, the optimization of mine or gold recovery plans, the permitting of a mine at the Livengood project, the potential for a production decision to be made, the potential commencement of any development of a mine at Livengood following a production decision, the Company’s business strategies, and the Company’s other business and financing plans and business trends, are forward-looking statements. Information concerning mineral resource estimates and the preliminary economic analysis thereof also may be deemed to be forward-looking statements in that it reflects a prediction of the mineralization that would be encountered, and the results of mining it, if a mineral deposit were developed and mined.

Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate, proposed, planned, potential and similar expressions, or are those, which, by their nature, refer to future events. The Company cautions investors that any forward-looking statements by the Company are not guarantees of future results or performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, risks associated with the timing and pricing of the second stage of the Offering, completion of the second stage of the Offering, regulatory approval/acceptance of the second stage of the Offering, the use of proceeds from the Offering and other risks and uncertainties disclosed in the Company’s Annual Information Form filed with certain securities commissions in Canada and the Company’s annual report on Form 40-F as filed with the United States Securities and Exchange Commission (the “SEC”), and other information released by the Company and filed with the appropriate regulatory agencies. All of the Company’s Canadian public disclosure filings may be accessed via www.sedar.com and its United States public disclosure filings may be accessed via www.sec.gov, and readers are urged to review these materials, including the technical reports filed with respect to the Company’s Livengood Project.

This press release is not, and is not to be construed in any way as, an offer to buy or sell securities in the United States.

NR12-21

Contacts:
International Tower Hill Mines Ltd.
Michelle Stachnik
Manager – Investor Relations
720-881-7646 Ext 203 or Toll-Free: 1-855-208-4642
mstachnik@ithmines.com

Ladenburg (LTS) Co-Manages ARMOUR Residential REIT Pricing of Public 55M Share Offering

VERO BEACH, Fla., Aug. 3, 2012 (GLOBE NEWSWIRE) — ARMOUR Residential REIT, Inc. (NYSE:ARR) (NYSE: ARR PrA) and (NYSE MKT, LLC: ARR.WS) (“ARMOUR” or the “Company”) announced today that it has priced an underwritten public offering of 55,000,000 shares of common stock. ARMOUR has granted the underwriters a 30-day option to purchase up to 8,250,000 additional shares of common stock. The underwriters are offering the shares in one or more transactions in the over-the-counter market or through negotiated transactions at market prices or at negotiated prices. The offering is expected to close on August 8, 2012.

BofA Merrill Lynch, Barclays, Citigroup, Credit Suisse and Deutsche Bank Securities are joint book-running managers of the offering. JMP Securities, Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE Amex:LTS), and Mitsubishi UFJ Securities are co-managers of the offering.

The Company intends to use the net proceeds of the offering to acquire additional agency securities as market conditions warrant and for general corporate purposes.

A well-known seasoned issuer registration statement relating to the offered securities has been filed with the Securities and Exchange Commission (“SEC”) and became effective automatically upon filing. The offering is being made only by means of a prospectus supplement and accompanying base prospectus. Copies of the preliminary prospectus supplement and the related prospectus for the proposed offering may be obtained by contacting: BofA Merrill Lynch, Attn: Prospectus Department, 222 Broadway, 7^th Floor, New York, NY 10038, or by emailing dg.prospectus_requests@baml.com; Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Telephone: (888) 603-5847, or by emailing barclaysprospectus@broadridge.com; Citigroup, Attention: Prospectus Department, Brooklyn Army Terminal, 140 58th Street, 8th Floor, Brooklyn, New York 11220, Telephone: (800) 831-9146, or by emailing batprospectusdept@citi.com; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY, 10010, Telephone: (800) 221-1037, or by emailing newyork.prospectus@credit-suisse.com; Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, Telephone: (800) 503-4611, or by emailing prospectus.cpdg@db.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of the Company’s securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

ARMOUR Residential REIT, Inc.

ARMOUR is a Maryland corporation that invests primarily in hybrid adjustable rate, adjustable rate and fixed rate residential mortgage-backed securities (“RMBS”) issued or guaranteed by U.S. Government-chartered entities. ARMOUR is externally managed and advised by ARMOUR Residential Management LLC (“ARRM”). ARMOUR Residential REIT, Inc. has elected to be taxed as a real estate investment trust (“REIT”) for U.S. Federal income tax purposes, commencing with ARMOUR’s taxable year ended December 31, 2009.

Safe Harbor

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

CONTACT: Investor Contact:

         Jeffrey Zimmer
         Co-Chief Executive Officer,
         Chief Financial Officer, President and Co-Vice Chairman
         ARMOUR Residential REIT, Inc.
         (772) 617-4340

Origin Agritech (SEED) to Announce FY2012 Q3 Financial Results on August 7

BEIJING, Aug. 3, 2012 /PRNewswire-Asia/ — Origin Agritech Limited (NASDAQ: SEED) (“Origin” or the “Company”), a technology-focused supplier of hybrid and genetically modified crop seeds in China, today announced that the Company will report results for its fiscal year 2012 third quarter ended June 30, 2012, before the market opens on Tuesday, August 7, 2012.

The Company will host a teleconference on August 7, 2012, at 8:00 a.m. ET / 8:00 p.m. Beijing time to discuss the results. To participate in the call, please dial +1-877-407-9210 in North America, or +1-201-689-8049 internationally, approximately 5 minutes prior to the scheduled start time.

A replay of the call will be available shortly after the conference call through 11:59 p.m. ET on September 7, 2012. The replay dial-in numbers are: U.S. toll free number +1-877-660-6853, or the international number is +1-201-612-7415; using Account “286” and Conference ID “398588” to access the replay.

About Origin

Founded in 1997 and headquartered in Zhong-Guan-Cun (ZGC) Life Science Park in Beijing, Origin Agritech Limited (NASDAQ GS: SEED) is China’s leading agricultural biotechnology company, specializing in crop seed breeding and genetic improvement, seed production, processing, distribution, and related technical services. Leading the development of Genetically Modified (GM) technology, Origin Agritech’s phytase corn was the first transgenic corn to receive the Bio-Safety Certificate from China’s Ministry of Agriculture. Over the years, Origin has established a robust GM seed pipeline including products with glyphosate tolerance and pest resistance (Bt) traits. Staffed by approximately 800 employees, Origin operates production and processing centers and breeding stations nationwide with sales centers located in key crop-planting regions. The Company also operates one winter nursery in Hainan province. Product lines are vertically integrated for corn, rice and canola seeds. For further information, please log on to the Company’s website at: www.originseed.com.cn

Forward Looking Statement

This release contains forward-looking statements. All forward-looking statements included in this release are based on information available to us on the date hereof. These statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results to differ materially from those implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “targets,” “goals,” “projects,” “continue,” or variations of such words, similar expressions, or the negative of these terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Neither we nor any other person can assume responsibility for the accuracy and completeness of forward-looking statements. Important factors that may cause actual results to differ from expectations include, but are not limited to, those risk factors discussed in Origin’s filings with the SEC including its annual report on Form 20-F to be filed. We undertake no obligation to revise or update publicly any forward-looking statements for any reason.

CONTACT:

Origin Agritech Limited
James Chen
Chief Financial Officer
james.chen@originseed.com.cn

Grayling
Shiwei Yin, 646-284-9474
shiwei.yin@grayling.com

Corporate Video Demonstrates SEFE’s (SEFE) Revolutionary Atmospheric Energy System

ATLANTA, GA — (Marketwire) — 08/03/12 — SEFE, Inc. (OTCBB: SEFE) (OTCQB: SEFE) (the “Company”), a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, today announced the production of a short but stimulating video featuring SEFE CEO Don Johnston and Director of Engineering Mike Hurowitz, who explain the Company’s revolutionary and unique strategy to change the future of electricity generation on a global scale.

The complete video production can be viewed at http://sefe.missionir.com/sefe/corporate-video.html.

The idea behind SEFE’s green energy solution dates back to the 1920s. Today, SEFE is progressively working to advance that idea into a sustainable and abundant energy source. “If we’re just a little bit successful it could have a meaningful impact on not only the United States but the world,” Johnston states in the video.

SEFE is rapidly working to establish itself as a key player in the burgeoning green space market, which is positioned to outpace the coal, nuclear and fossil fuel sectors. “If we can pull this electricity down consistently, that’s a resource that’s completely untapped; no one is doing this… we have a potential here to do something revolutionary,” Hurowitz emphasizes.

About SEFE, Inc.
SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

SEFE, Inc.
Justin Ackerman
714-495-1927
ir@sefelectric.com

Mission Investor Relations
404-941-8975
Investors@MissionIR.com

Repligen (RGEN) Announces Strategic Focus on Bioprocessing, Reports Q2 FY12 Financials

Repligen Corporation (NASDAQ: RGEN) today reported financial results for its second quarter and year-to-date period ended June 30, 2012. In addition, the Company announced that it will focus its corporate strategy and resources on the growth of its core bioprocessing business, which achieved record sales during the quarter. As a result of this defined strategic focus, the Company will seek a development and commercialization partner for its pancreatic imaging product candidate, RG1068.

The Company reported total revenue for the three-month period ended June 30, 2012 of $15,524,000 compared to $7,654,000 for the same period in 2011. Revenue growth for the second quarter of 2012 was driven by the Company’s expanded bioprocessing business, which generated $11,659,000 in product revenue compared to $4,358,000 for the same period in 2011, an increase of 168%. Royalty and research revenue for the three-month period ended June 30, 2012, consisting primarily of royalty payments from Bristol-Myers Squibb on its U.S. sales of Orencia^®, was $3,865,000 compared to $3,295,000 for the same period in 2011. June 30, 2012 marks the end of the second fiscal quarter for which the Company is reporting consolidated financial results since its acquisition of Novozymes Biopharma Sweden AB (now Repligen Sweden AB) in December 2011.

“Our strong second quarter and year-to-date financial performance was highlighted by revenue gains in our recently expanded bioprocessing business,” said Walter C. Herlihy, Ph.D., President and CEO of Repligen. “The successful integration of Repligen Sweden, our longstanding expertise in bioprocessing product development and manufacturing, and the continued strength in the global market for biologic drugs were key factors in our decision to focus corporate strategy and resources on bioprocessing. We are committed to building Repligen into a sustainably profitable, best-in-class life sciences company focused on providing high-value consumables used to manufacture biologics.”

Operating expenses for the three-month period ended June 30, 2012 were $14,206,000 compared to $7,775,000 for the same period in 2011, an increase of $6,431,000 or 83%. These operating expenses included an increase in cost of product revenue of $5,792,000 due to higher sales, and an increase in selling, general and administrative expenses of $1,129,000 compared to the same three-month period in 2011. These increases were primarily due to the addition of Repligen Sweden AB in December 2011. In addition, research and development expenses decreased by $612,000 during the three-month period ended June 30, 2012 compared to the same period in 2011. Expenses for the second quarter included $511,000 for employee salary and severance associated with our cost reduction initiatives at Repligen Sweden. Net income for the three-month period ended June 30, 2012 was $1,570,000 or $0.05 per diluted share, compared to a net loss of $56,000 or $0.00 per diluted share for the same period in 2011. Cash and investments as of June 30, 2012 were $39,232,000 compared to $36,025,000 as of December 31, 2011.

For the six-month period ended June 30, 2012, total revenue was $28,348,000 compared to total revenue of $13,560,000 for the same period in 2011. Operating expenses for the six-month period ended June 30, 2012 were $25,863,000 compared to $15,768,000 for the same period in 2011. Net income for the six-month period ended June 30, 2012 was $2,796,000 or $0.09 per diluted share compared to a net loss of $2,086,000 or $0.07 per diluted share for the same period in 2011.

Based on current sales projections, the Company is raising revenue guidance for fiscal year 2012 from its previous estimate of $52 million to $55 million to its current estimate of $55 million to $57 million. Included in this total revenue estimate is bioprocessing revenue, for which the Company is increasing its previous estimate of $39 million to $41 million to its current estimate of $41 million to $43 million. The Company is also adjusting its estimate for net profit to $5 million to $7 million for fiscal year 2012; an increase based in part on anticipated reductions in research and development costs associated with its diagnostic and orphan drug assets.

Corporate Update

Repligen corporate events for the year-to-date included the following:

Bioprocessing

• Our acquisition of Novozymes Biopharma Sweden AB in December 2011 positioned Repligen as a world-leading manufacturer of critical products for manufacturing biologic drugs, including monoclonal antibodies. During the second quarter of 2012 we continued a process to integrate Repligen Sweden AB into Repligen’s U.S. operations. We believe that the cost reduction initiatives we have implemented thus far will contribute to our goal to optimize operating efficiencies and increase bioprocessing margins.
• Our commercial launch in February of pre-packed OPUS™ chromatography columns for clinical-stage manufacturing has generated significant interest from biopharmaceutical customers. The OPUS™ line is positioned to benefit from an ongoing increase in the market demand for disposable technologies in biopharmaceutical manufacturing. These single-use technologies can substantially decrease production time and increase cGMP manufacturing facility flexibility. In addition, our “Open Platform, User Specified” OPUS™ system is unique in being customizable for the specific requirements of our customers who manufacture a wide range of clinical-stage biologic drugs.

Imaging

• In June, we received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) with respect to our new drug application (NDA) for RG1068 (synthetic human secretin). The RG1068 NDA was submitted for the improved detection of pancreatic duct abnormalities in patients with known or suspected pancreatitis. The CRL indicated that additional trial data will be required to support potential approval of the NDA.
• Consistent with our decision to focus corporate strategy on bioprocessing, and considering the time and resources required to conduct additional clinical studies, the Company will seek a development and commercialization partner for RG1068. Given the positive efficacy and safety data observed to date for RG1068, we continue to interact with the FDA to gain further information regarding a study protocol that a potential partner could adopt to address the agency’s requirements. In conjunction with this decision, we will cease to prosecute our European Union Marketing Authorization Application for RG1068.

CNS Pipeline

• In April, we announced at the annual meeting of the American Academy of Neurology the positive topline results from a completed Phase 1 study of our novel small molecule enzyme inhibitor, RG3039, for the potential treatment of spinal muscular atrophy (SMA). We are seeking partners to fund future development of this program, which has received financial support from the Muscular Dystrophy Association (MDA).
• A Phase 1 trial of the Company’s novel HDAC inhibitor RG2833 was initiated in March and is currently ongoing. RG2833 is being studied as a potential treatment for Friedreich’s ataxia (FA). This single ascending dose crossover study in up to 20 adult FA patients is designed to evaluate the pharmacokinetic and safety profile of RG2833 as well as biomarkers indicative of a drug response. We are pursuing partners to fund future development of this program which currently receives financial support from a number of organizations including the MDA, GoFAR, and the Friedreich’s Ataxia Research Alliance.

Corporate

• In June, Repligen stock was added to the Russell 2000^® index in conjunction with Russell Investments’ annual index reconstitution. We believe that the inclusion of RGEN will enhance visibility of the Company among institutions that rely on equity indexes as part of their investment strategy.

Conference Call

Repligen will host a conference call and webcast today, August 2, 2012, at 8:30 a.m. EDT, to discuss second quarter 2012 financial results, corporate developments for the year to date and other business matters. The live call can be accessed by dialing (866) 543-6407 for domestic callers or (617) 213-8898 for international callers. Dial-in participants must provide the passcode 51406171. The webcast can be accessed at the Investors section of Repligen’s website www.repligen.com. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (888) 286-8010 for domestic callers and (617) 801-6888 for international callers. Replay listeners must provide the passcode 79641908.

About Repligen Corporation

Repligen Corporation is a life sciences company that develops, manufactures and markets bioprocessing products for life sciences and biopharmaceutical manufacturing customers worldwide. We are a leading manufacturer of both native and recombinant forms of Protein A, critical reagents used in the manufacture of monoclonal antibodies, a type of biologic drug. We also supply several growth factor products used to increase cell culture productivity during the biomanufacturing process. In the burgeoning area of disposable biomanufacturing technologies, we have developed and market a series of OPUS™ (Open Platform User Specified) single-use chromatography columns used in the purification process for clinical-stage biologics. In addition to our core bioprocessing business, Repligen has a portfolio of clinical-stage partnering assets that includes two central nervous system (CNS) orphan drug candidates and a pancreatic imaging agent in Phase 3 development. Repligen’s corporate headquarters are located at 41 Seyon Street, Building #1, Suite 100, Waltham, MA 02453. Additional information can be found at www.repligen.com.

This press release contains forward-looking statements, which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that statements in this press release which are not strictly historical statements, including, without limitation, express or implied statements regarding future financial performance and position, our strategic decision to focus on the growth of our bioprocessing business, the FDA and EMA review of our NDA and MAA for RG1068 (SecreFlo™) and additional clinical data that may be required in connection therewith, plans and objectives for future operations, our ability to successfully negotiate and consummate partnering transactions for our clinical stage assets, including RG1068, RG3039 and RG2833, plans and objectives for product development, our market share and product sales and other statements identified by words like “believe,” “expect,” “may,” “will,” “should,” “seek,” or “could” and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, risks associated with: our ability to successfully grow our bioprocessing business; our ability to successfully negotiate and consummate development and commercialization partnerships for our portfolio of therapeutic and diagnostic assets on acceptable terms, if at all; our ability to develop and commercialize products and the market acceptance of our products; reduced demand for our products that adversely impacts our future revenues, cash flows, results of operations and financial condition; our ability to obtain regulatory approvals; the success of current and future collaborative or supply relationships; our ability to compete with larger, better financed bioprocessing, pharmaceutical and biotechnology companies; our ability to successfully integrate Repligen Sweden AB; the success of our clinical trials; new approaches to the treatment of our targeted diseases; our compliance with all FDA and EMEA regulations; our ability to obtain, maintain and protect intellectual property rights for our products; the risk of litigation regarding our intellectual property rights; our limited sales capabilities; our volatile stock price; and other risks detailed in Repligen’s Annual Report on Form 10-K on file with the Securities and Exchange Commission and the other reports that Repligen periodically files with the Securities and Exchange Commission. Actual results may differ materially from those Repligen contemplated by these forward-looking statements. These forward looking statements reflect management’s current views and Repligen does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.

AMSC (AMSC) Reports First Quarter Financial Results

Company Exceeds Financial Guidance and Posts Solid Year-Over-Year Growth

DEVENS, Mass., Aug. 2, 2012 (GLOBE NEWSWIRE) — AMSC (Nasdaq:AMSC), a global solutions provider serving wind and grid leaders, today reported financial results for its first quarter of fiscal year 2012 ended June 30, 2012.

Revenues for the first quarter of fiscal 2012 were $28.7 million, which compares with $9.1 million for the first quarter of fiscal 2011. The year-over-year increase was driven by strong growth in the company’s Wind and Grid reporting segments.

For the first quarter of fiscal 2012, AMSC reported a net loss of $10.3 million, or $0.20 per share. This figure includes a non-cash benefit of approximately $7.3 million for the settlement of adverse purchase commitments with certain vendors as well as a $2.4 million non-cash “mark-to-market” charge driven by the re-valuation of the derivative liability and warrants associated with the company’s recently completed debt financings. For the first quarter of fiscal 2011, AMSC’s net loss was $37.7 million, or $0.74 per share.

The company’s non-GAAP net loss for the first quarter of fiscal 2012 was $10.2 million, or $0.20 per share. This compares with a non-GAAP net loss of $30.8 million, or $0.61 per share, for the first quarter of fiscal 2011. Please refer to the financial table below for a reconciliation of GAAP to non-GAAP results.

AMSC’s cash, cash equivalents, marketable securities and restricted cash at June 30, 2012 totaled $87.1 million. This compares with $66.2 million as of March 31, 2012. The increase in cash, cash equivalents, marketable securities and restricted cash was driven by the financings that were completed and announced in the first quarter of fiscal 2012.

The company’s total backlog as of June 30, 2012 was approximately $269 million. This compares with approximately $291 million as of March 31, 2012 and $225 million as of June 30, 2011.

“AMSC continues to meet its financial objectives, delivering a strong year-over-year revenue increase and net loss reduction in the first fiscal quarter,” said AMSC President and Chief Executive Officer Daniel P. McGahn. “With key contributions coming from China, Korea and India in our Wind segment and Australia and Romania in our Grid segment, our revenue streams remained diverse and well balanced. This, coupled with the cost reduction initiatives that were put into place in past quarters, enabled us to once again improve our bottom-line performance while minimizing cash usage.”

Looking Forward

“We expect our second-quarter revenues to be relatively flat year over year before growth returns in the second half of our fiscal year,” said McGahn. “For fiscal year 2012 as a whole, we continue to focus on maintaining our strong track record of execution and are committed to driving year-over-year growth while prudently managing our expenses and our cash as we work toward sustainable profits and positive cash flows.”

For the quarter ending September 30, 2012, AMSC expects that its revenues will exceed $20 million. AMSC expects that its net loss for the second quarter of fiscal 2012 will be less than $22 million, or $0.43 per share. This guidance assumes no impact from mark-to-market adjustments related to the derivative liability and warrants. AMSC expects that its non-GAAP net loss for the second quarter of fiscal 2012 will be less than $17 million, or $0.33 per share. AMSC estimates that it will have more than $70 million in cash, cash equivalents, marketable securities and restricted cash on September 30, 2012.

Conference Call Reminder

In conjunction with this announcement, AMSC management will participate in a conference call with investors beginning at 10:00 a.m. Eastern Time today to discuss the company’s results and its business outlook. Those who wish to listen to the live or archived conference call webcast should visit the “Investors” section of the company’s website at http://www.amsc.com/investors. The live call also can be accessed by dialing 719-325-2486 and using conference ID 1467837.

About AMSC (Nasdaq:AMSC)

AMSC generates the ideas, technologies and solutions that meet the world’s demand for smarter, cleaner … better energy. Through its Windtec™ Solutions, AMSC enables manufacturers to launch best-in-class wind turbines quickly, effectively and profitably. Through its Gridtec™ Solutions, AMSC provides the engineering planning services and advanced grid systems that optimize network reliability, efficiency and performance. The company’s solutions are now powering gigawatts of renewable energy globally and enhancing the performance and reliability of power networks in more than a dozen countries. Founded in 1987, AMSC is headquartered near Boston, Massachusetts with operations in Asia, Australia, Europe and North America. For more information, please visit www.amsc.com.

The AMSC logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11339

AMSC, Windtec and Gridtec are trademarks or registered trademarks of American Superconductor Corporation. All other brand names, product names, trademarks or service marks belong to their respective holders.

Any statements in this release about future expectations, plans and prospects for the company, including without limitation our prospects for future growth, expectations regarding the sufficiency of our existing cash balance, expectations regarding future financial results and liquidity and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements represent management’s current expectations and are inherently uncertain. There are a number of important factors that could materially impact the value of our common stock or cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include: our success in addressing the wind energy market is dependent on the manufacturers that license our designs; we may not realize all of the sales expected from our backlog of orders and contracts; our business and operations would be adversely impacted in the event of a failure or security breach of our information technology infrastructure; our success is dependent upon attracting and retaining qualified personnel and our inability to do so could significantly damage our business and prospects; we rely upon third-party suppliers for the components and subassemblies of many of our Wind and Grid products, making us vulnerable to supply shortages and price fluctuations, which could harm our business; many of our revenue opportunities are dependent upon subcontractors and other business collaborators; if we fail to implement our business strategy successfully, our financial performance could be harmed; problems with product quality or product performance may cause us to incur warranty expenses and may damage our market reputation and prevent us from achieving increased sales and market share; our contracts with the U.S. government are subject to audit, modification or termination by the U.S. government and include certain other provisions in favor of the government – the continued funding of such contracts remains subject to annual congressional appropriation which, if not approved, could reduce our revenue and lower or eliminate our profit; we may acquire additional complementary businesses or technologies, which may require us to incur substantial costs for which we may never realize the anticipated benefits; many of our customers outside of the United States are, either directly or indirectly, related to governmental entities, and we could be adversely affected by violations of the United States Foreign Corrupt Practices Act and similar worldwide anti-bribery laws outside the United States; we have limited experience in marketing and selling our superconductor products and system-level solutions, and our failure to effectively market and sell our products and solutions could lower our revenue and cash flow; we have a history of operating losses, and we may incur additional losses in the future; our operating results may fluctuate significantly from quarter to quarter and may fall below expectations in any particular fiscal quarter; we may require additional funding in the future and may be unable to raise capital when needed; our new debt obligations include certain covenants and other events of default – should we not comply with the covenants or incur an event of default, we may be required to repay our debt obligations in cash, which could have an adverse effect on our liquidity; we have recorded a liability for adverse purchase commitments with certain of our vendors – should we be required to settle these liabilities in cash, our liquidity could be adversely affected; if we fail to maintain proper and effective internal controls over financial reporting, our ability to produce accurate and timely financial statements could be impaired and may lead investors and other users to lose confidence in our financial data; we may be required to issue performance bonds or provide letters of credit, which restricts our ability to access any cash used as collateral for the bonds or letters of credit; changes in exchange rates could adversely affect our results from operations; growth of the wind energy market depends largely on the availability and size of government subsidies and economic incentives; we depend on sales to customers in China, and global conditions could negatively affect our operating results or limit our ability to expand our operations outside of China; changes in China’s political, social, regulatory and economic environment may affect our financial performance; our products face intense competition, which could limit our ability to acquire or retain customers; our international operations are subject to risks that we do not face in the United States, which could have an adverse effect on our operating results; adverse changes in domestic and global economic conditions could adversely affect our operating results; we may be unable to adequately prevent disclosure of trade secrets and other proprietary information; our patents may not provide meaningful protection for our technology, which could result in us losing some or all of our market position; the commercial uses of superconductor products are limited today, and a widespread commercial market for our products may not develop; there are a number of technological challenges that must be successfully addressed before our superconductor products can gain widespread commercial acceptance, and our inability to address such technological challenges could adversely affect our ability to acquire customers for our products; we have not manufactured our Amperium wire in commercial quantities, and a failure to manufacture our Amperium wire in commercial quantities at acceptable cost and quality levels would substantially limit our future revenue and profit potential; third parties have or may acquire patents that cover the materials, processes and technologies we use or may use in the future to manufacture our Amperium products, and our success depends on our ability to license such patents or other proprietary rights; our technology and products could infringe intellectual property rights of others, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and disrupt our business; we have filed a demand for arbitration and other lawsuits against our former largest customer, Sinovel, regarding amounts we contend are overdue – we cannot be certain as to the outcome of these proceedings; we have been named as a party to purported stockholder class actions and stockholder derivative complaints, and we may be named in additional litigation, all of which will require significant management time and attention, result in significant legal expenses and may result in an unfavorable outcome, which could have a material adverse effect on our business, operating results and financial condition; our 7% convertible note contains warrants and provisions that could limit our ability to repay the note in shares of common stock and should the note be repaid in stock, shareholders could experience significant dilution; our common stock has experienced, and may continue to experience, significant market price and volume fluctuations, which may prevent our stockholders from selling our common stock at a profit and could lead to costly litigation against us that could divert our management’s attention. Reference is made to many of these factors and others in the “Risk Factors” section of the company’s most recent quarterly or annual report filed with the Securities and Exchange Commission. In addition, any forward-looking statements included in this release represent the company’s expectations as of the date of this release. While the company anticipates that subsequent events and developments may cause the company’s views to change, the company specifically disclaims any obligation to update these forward-looking statements. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this release.

RECONCILIATION OF FORECAST GAAP NET LOSS TO NON-GAAP NET LOSS
(In millions, except per share data)
	Three months ending September 30, 2012
Net loss	$ (22.0)
Amortization of acquisition-related intangibles	0.1
Stock-based compensation	2.5
Non-cash interest expense	2.4
Non-GAAP net loss	$ (17.0)
Non-GAAP net loss per share	$ (0.33)
Shares outstanding	51.5

Note: Non-GAAP net income (loss) is defined by the company as net income (loss) before adverse purchase commitments (recoveries) losses, net; stock-based compensation; amortization of acquisition-related intangibles; restructuring and impairment charges; executive severance; Sinovel litigation costs; margin on zero cost-basis accounting; non-cash interest expense; change in fair value of derivative liability and warrants and other unusual charges; net of any tax effects related to these items. The company believes non-GAAP net income (loss) assists management and investors in comparing the company’s performance across reporting periods on a consistent basis by excluding these non-cash or non-recurring charges that it does not believe are indicative of its core operating performance. The company also regards non-GAAP net income (loss) as a useful measure of operating performance and cash flow to complement operating income, net income (loss) and other GAAP financial performance measures. In addition, the company uses non-GAAP net (loss) income as a factor in evaluating management’s performance when determining incentive compensation and to evaluate the effectiveness of its business strategies.

Generally, a non-GAAP financial measure is a numerical measure of a company’s performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. The non-GAAP measures included in this release, however, should be considered in addition to, and not as a substitute for or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of non-GAAP to GAAP net income is set forth in the table above.

CONTACT: AMSC
         Jason Fredette
         Phone: 978-842-3177
         Email: jason.fredette@amsc.com

SEFE (SEFE) Announces Successful Flight Test Report

SEFE, Inc. (OTCBB/OTCQB: SEFE) (the “Company”), a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, is pleased to announce the completion of helicopter flight testing conducted on a ranch owned by Lead Scientist Ryan Coulson’s family. Broken into three separate lifts, the test demonstrated the ability of the detector to measure charge density in the earth’s atmosphere.

The detector performed as expected electrically, and a thorough data set was captured for the location. The final flight path consisted of continuous laps around the property, increasing the elevation for each lap. Data was carefully gathered during the entire flight up to a maximum elevation just below the cloud ceiling, which was about 2100 ft. above ground level.

“The excitement of our team continues to build as we perfect our technology and discover the most effective methods of harnessing atmospheric electricity at the lowest cost,” commented SEFE CEO Don Johnston. “The data collected will help significantly in determining how much electricity can be generated by each unit over a period of time based on location, altitude, weather and other factors.”

“SEFE will continue to move forward with its data collection initiatives and make additional improvements, while securing additional patents to protect our technology internationally and developing strategic alliances to further our research and maximize our potential,” concluded Mr. Johnston.

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Echo Therapeutics (ECTE) Announces Positive Clinical Trial Results of Symphony® tCGM System

Data demonstrate that Symphony accurately monitors glucose levels in hospital patients

PHILADELPHIA, Aug. 1, 2012 /PRNewswire/ —  Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude® SkinPrep System for transdermal drug delivery, today announced positive results from its clinical trial of the Symphony tCGM System in major general surgery and cardiothoracic surgery patients.  This study is the second of two studies in critically ill patients.

(Logo: http://photos.prnewswire.com/prnh/20120801/NE50071LOGO)

Data from this study demonstrate that Symphony successfully and continuously monitored glucose levels in the intensive care unit at Thomas Jefferson University Hospital in Philadelphia, Pennsylvania.  Data analysis demonstrated that Symphony accurately read glucose levels with a mean absolute relative difference (MARD), or error rate of 9.0%.  The Continuous Glucose-Error Grid analysis (CG-EGA) showed that 98.9% of the readings were clinically accurate (A) and 0.3% were benign (B) errors with a combined A+B of 99.2%

“We are extremely pleased with the positive results of this trial which demonstrate that Symphony can accurately read glucose in critically ill patients who have undergone major general surgery.  Additionally, this study demonstrates that Symphony performs consistently well in yet another patient group.  Data from this study are very similar to patients in other studies with differing disease states,” said Patrick T. Mooney, M.D., Chairman and CEO of Echo Therapeutics.  “We believe, if used effectively, Symphony will help prevent hypo- and hyperglycemic excursions in patients and will improve patient outcomes.”

Jeffrey I. Joseph, D.O., Professor of Anesthesiology and Director of the Jefferson Artificial Pancreas Center at Thomas Jefferson University, and the Principal Investigator of the study, added: “The Echo Therapeutics’ continuous glucose monitoring system safely and accurately measured the concentration of glucose in a wide variety of surgical patients managed in the ICU. Study physicians and nurses found the non-invasive, wireless continuous glucose monitoring system easy to apply and utilize in the critical care environment.  Current methods of glucose monitoring in the hospital are intermittent, labor intensive, prone to error, and expose the caregiver to blood.  Hospitals rarely monitor glucose frequently enough to minimize hyperglycemia and avoid hypoglycemia. Thus, there is great clinical need in the hospital for a continuous glucose monitoring system that reliably provides a real-time glucose measurement every minute or two.  The bedside clinician will use the glucose trend information to support glycemic control protocols, leading to improved clinical outcome.  The Echo Therapeutics’ Symphony continuous glucose monitoring system demonstrated satisfactory safety, accuracy, and reliability during the clinical trial at Thomas Jefferson University Hospital.”

Study Results

Using over 1,200 Symphony tCGM glucose readings from fifteen (15) study subjects paired with reference blood glucose measurements, CG-EGA showed that 98.9% of the readings were clinically accurate and 0.3% were benign errors with a combined A+B of 99.2%.  The MARD for the study was 9.0%.  There were no adverse events reported from the Prelude skin preparation or the Symphony tCGM biosensor.  The range of glucose values was 74 – 272 mg/dL.

Study Design

This study was the second of two studies designed to evaluate the performance of Echo’s Symphony tCGM System in the critical care setting.  The study was performed at Thomas Jefferson University Hospital and enrolled fifteen (15) adult patients. The skin of each patient was prepared using Prelude and a Symphony tCGM biosensor was applied to the skin site after transfer to critical care.  Reference blood samples were taken from arterial line catheters at 30-minute intervals and measured on a YSI 2300 STAT Plus Glucose Analyzer.  The data collected by Symphony was blinded to study subjects and Jefferson clinical staff.  At the conclusion of the study period, the test sites were inspected for redness or other undesirable effects.

Analytical Methods

Continuous data from the Symphony tCGM System were compared to reference measurements from the YSI 2300 STAT Plus Glucose Analyzer.  Those reference measurements were paired with the Symphony results through a data analysis algorithm.  The primary statistical analytical tools used to evaluate the performance of Symphony were the Continuous Glucose-Error Grid analysis (CG-EGA) and Mean Absolute Relative Difference (MARD).  The CG-EGA is a categorization of all data pairs based on the clinical significance of the accuracy.  Accurate readings result in the same clinical decision when based on the CGM value versus the blood glucose value.  Benign errors lead to the same clinical outcome as accurate readings even though the actual clinical decision may differ.  Erroneous readings lead to clinical errors.  CGM performance is measured as the sum of accurate readings and benign errors.  Numerical accuracy is measured using MARD, an error calculation tool that was used to measure the absolute value of the average relative difference between Symphony and the reference measurements, on a percentage basis.

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units.  Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s and its partners’ ongoing studies, including the safety and efficacy of Echo’s Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo’s Symphony tCGM and Prelude SkinPrep Systems, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its Annual Report on Form 10-K for the year ended December 31, 2011, its Quarterly Reports on Form 10-Q, and its Current Reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Christine H. Olimpio
Director, Investor Relations and Corporate Communications
colimpio@echotx.com
(215) 717-4104

Connect With Us:
– Visit our website at www.echotx.com
– Follow us on Twitter at www.twitter.com/echotx
– Join us on Facebook at www.facebook.com/echotx

Tranzyme Pharma (TZYM) to Present at the Canaccord Genuity 32nd Annual Growth Conference

RESEARCH TRIANGLE PARK, N.C., Aug. 1, 2012 (GLOBE NEWSWIRE) — Tranzyme Pharma (Nasdaq:TZYM), today announced that Vipin K. Garg, Ph.D., President and CEO, and Richard I. Eisenstadt, Vice President, Finance and CFO, will present at the Canaccord Genuity 32^nd Annual Growth Conference taking place at the Intercontinental Hotel in Boston, MA August 14-16, 2012. Tranzyme’s presentation is scheduled for Tuesday, August 14^th at 1:00 pm ET in the Vancouver Room followed by a breakout session.

A live audio webcast of the presentation will be available in the “Investors” section of the Tranzyme Pharma website, www.tranzyme.com, following the conference.

About Tranzyme Pharma

Tranzyme Pharma is a late-stage biopharmaceutical company focused on discovering, developing and commercializing novel, mechanism-based therapeutics for the treatment of upper gastrointestinal (GI) motility disorders. While approximately 40 percent of people in the U.S. are affected by these persistent and recurring conditions which disrupt the normal movement of food throughout the GI tract, currently there are a limited number of safe and effective treatment options. Tranzyme is developing TZP-102, an oral ghrelin agonist for treating the symptoms associated with chronic upper GI motility disorders. Enrollment in a multinational Phase 2b trial evaluating TZP-102 in diabetic patients with gastroparesis is ongoing; top-line data are expected by year-end 2012. By leveraging its proprietary drug discovery technology, Tranzyme is committed to pursuing first-in-class medicines to address areas of significant unmet medical needs.

Further information about Tranzyme Pharma can be found on the Company’s web site at www.tranzyme.com.

CONTACT: Corporate Inquiries:
         Susan Sharpe
         Director, Corporate Communications
         (919) 328-1109
         ssharpe@tranzyme.com

         Investor Inquiries:
         David Carey
         Lazar Partners, Ltd.
         (212) 867-1768
         dcarey@lazarpartners.com

Frontier Communications (FTR) to Carry Pac-12 Networks

FiOS® TV from Frontier Subscribers Will Enjoy Pac-12 Regional Sports Favorites When the Networks Launch on August 15, 2012

Frontier Communications today announced an agreement to provide the Pac-12 Networks to FiOS TV customers in the Pacific Northwest starting August 15, when the new networks launch. FiOS TV from Frontier will carry hundreds of live events and other specialty content including 35 football games and more than 130 men’s basketball games for fans of Washington and Oregon Pac-12 Conference teams.

“Frontier is dedicated to our local communities and proud to showcase the great tradition and excellence of Pac-12 sports to our FiOS TV customers in Oregon,” said Ken Gaffga, Oregon Senior Vice President and General Manager, Frontier Communications. “FiOS TV from Frontier will be the place where fans can follow all the exciting college action of the powerhouse Pac-12 Conference.”

During the first three weeks of the 2012 football season, the Pac-12 Networks will televise five games from Oregon, Oregon State, Washington and Washington State, including San Diego State at Washington and OSU’s home opener in week one, as well as Fresno State at Oregon and head coach Mike Leach’s home debut at Washington State in week two.

“With football season and all of the Fall sports fast approaching, the Pac-12 Networks will be providing great content to our fans on a daily basis, and we are delighted that Frontier customers are now part of this experience,” said Gary Stevenson, President of Pac-12 Enterprises. “We are in a unique position to tell stories that haven’t been told before about our student-athletes, our coaches and our universities. Frontier customers will now have the opportunity to follow and become even more engaged with their favorite teams.”

In addition to all of the live games, the Pac-12 Networks will feature shoulder programming that will include pregame and postgame shows, football coaches’ shows and Classic Games, among others. Frontier subscribers will also be able to watch games from all six regions on Pac-12 Now, the TV Everywhere platform that allows fans to watch games on connected devices like the computer and iPad.

Gaffga went on to say, “We listened to our Oregon customers who asked for the Pac-12 Networks on FiOS TV. We are thrilled to bring our customers the kind of programming that excites them.”

About Pac-12 Enterprises

Pac-12 Enterprises is the new content and multiplatform media company for the Pac-12 Conference, a leader in collegiate athletics that includes 12 of the most prestigious universities in the world and a nation-leading 451 NCAA titles across 27 sports. Headquartered in San Francisco, Pac-12 Enterprises was created in 2011 to develop and launch the Pac-12 Networks and Pac-12 Digital, and to control the distribution of the Pac-12 intellectual property rights in sports and other Conference initiatives.

Launching August 15, 2012, the Pac-12 Networks are full-time native HD linear networks available to video programming operators, dedicated solely to the Pac-12. It will consist of a national network and six regional feeds that will televise hundreds of live sporting events annually and provide 24/7 access to Pac-12 teams and universities. Pac-12 Digital encompasses the digital network, mobile, the university websites, social media and innovative digital initiatives across the company.

About Frontier Communications

Frontier Communications Corporation (NASDAQ: FTR) is an S&P 500 company and is included in the FORTUNE 500 list of America’s largest corporations. Frontier offers broadband, voice, satellite video, wireless Internet data access, entertainment services like TumTiki.com, data security solutions, bundled offerings and specialized bundles for residential customers, small businesses and home offices and advanced business communications for medium and large businesses in 27 states. Frontier’s approximately 15,500 employees are based entirely in the United States. More information is available at www.frontier.com.

Cardium’s (CXM) Excellagen® Named As Top 10 Innovation In Podiatry

SAN DIEGO, Aug. 1, 2012 /PRNewswire/ — Cardium Therapeutics (NYSE MKT: CXM) today announced that its professional-use Excellagen® (formulated collagen gel 2.6%) wound care product was selected as one of the top ten podiatry innovations in 2012 by the publication Podiatry Today. The Company also announced that it will be introducing Excellagen at the American Podiatric Medical Association (APMA) National Meeting (Booth 1910) being held August 16 – 19, 2012 in Washington, DC.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

The report, entitled “The Top 10 Innovations in Podiatry,” states that Excellagen, “A new topical gel may help foster improved healing in chronic wounds.” It is noted that “the product’s full-length collagen molecules are in their natural, fibrillar form, and are formulated in a unique physiologic buffer that ensures maintenance of the collagen molecule’s structure and function,” as stated by Arthur Tallis, DPM, a Fellow of the American Professional Wound Care Association and the American College of Foot and Ankle Surgeons, who was a clinical investigator in the multi-center Phase 2b MATRIX study. The article can be viewed online at http://www.podiatrytoday.com/top-10-innovations-podiatry?page=3 and will appear in the August 2012 print issue of Podiatry Today.

As reported by Podiatry Today, “Dr. Tallis has applied Excellagen following surgical debridement in the presence of blood cells and platelets,” and noted that “Excellagen activates human platelets, triggering the release of platelet-derived growth factors (PDGF).” With regard to the practice of podiatry and patient compliance, it was noted that “Excellagen can save time for the physician and patient as dressing changes are required only once a week.” In terms of ease of application and use, it was stated that “additional advantages of Excellagen are that no thawing or mixing of components is required prior to use,” and that “one can easily apply the formulation to wounds of all sizes and shapes, and the product achieves complete, even wound coverage without dripping.”

About Excellagen

Excellagen is an FDA-cleared highly-purified formulated collagen topical gel (2.6%) engineered for debridement and platelet activation and to support a favorable wound healing environment for non-healing lower extremity diabetic ulcers and other dermal wounds.  Excellagen’s unique high-molecular weight structured collagen formulation is topically applied through easy-to-control, pre-filled, sterile, single use syringes and its viscosity-optimized gel formulation is designed for application at only one or two week intervals.  Excellagen is intended for professional use following standard debridement procedures in the presence of blood cells and platelets, which are involved with the release of endogenous growth factors.  Following FDA clearance, Cardium conducted additional studies showing that Excellagen can activate platelets to trigger the release of Platelet-Derived Growth Factor (PDGF), which is recognized as an important wound healing facilitator.

Cardium’s market research indicates that physicians seek easy-to-use products to reduce preparation time and facilitate product application – and Excellagen’s unique, ready-to-use syringe-based collagen gel requires no thawing or mixing.  Because of its specialized formulation, only a thin layer needs to be applied over the wound area, and one syringe containing 0.5 cc of Excellagen covers wounds up to 5cm² in size using the supplied 24-gauge sterile, single-use flexible applicator tip.  To learn more about new Excellagen and for product ordering information, please visit http://www.excellagen.com/pdf/Excellagen-FactSheet-for-Physician.pdf and view the information video, Excellagen: A New Wound Care Pathway for Diabetic Foot Ulcers, at http://www.excellagen.com/excellagen-video.html.

About Cardium

Cardium is an asset-based, health sciences and regenerative medicine company focused on acquiring and strategically developing innovative products and businesses with the potential to address significant unmet medical needs and having definable pathways to commercialization, partnering or other economic monetizations. Cardium’s current portfolio includes the Tissue Repair Company, Cardium Biologics, and the Company’s in-house MedPodium Health Sciences healthy lifestyle product platform. The Company’s lead commercial product Excellagen^® topical gel for wound care management, has recently received FDA clearance for marketing and sale in the United States. Cardium’s lead clinical development product candidate Generx^® is a DNA-based angiogenic biologic intended for the treatment of patients with myocardial ischemia due to coronary artery disease. In addition, consistent with its capital-efficient business model, Cardium continues to actively evaluate new technologies and business opportunities. In July 2009, Cardium completed the sale of its InnerCool Therapies medical device business to Royal Philips Electronics, the first asset monetization from the Company’s biomedical investment portfolio. News from Cardium is located at www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations.  For example, there can be no assurance that we can successfully introduce Excellagen into wound care markets for the treatment of diabetic foot ulcers or other dermal wounds; that we can have Excellagen or our other products manufactured in a successful and cost-effective manner; that we can attract suitable commercialization partners for our products or that such partners will successfully commercialize our products; that our product or product candidates will not be unfavorably compared to other competitive products that may be regarded as safer, more effective, easier to use or less expensive; that results or trends observed in one clinical study or procedure will be reproduced in subsequent studies or procedures or in actual use; that clinical studies and regulatory clearances even if successful will lead to product advancement or partnering; that FDA or other regulatory clearances or other certifications, or other commercialization efforts will effectively enhance our businesses or their market value; that our products or product candidates will prove to be sufficiently safe and effective after introduction into a broader patient population; that our exchange listing compliance can be maintained; that new collaborative partners will be found; that additional product opportunities will be established; or that third parties on whom we depend will perform as anticipated.

Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and in the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our ability to obtain necessary funding, regulatory approvals and expected qualifications, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission.  We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2012 Cardium Therapeutics, Inc.  All rights reserved.

For Terms of Use Privacy Policy, please visit www.cardiumthx.com.

Cardium Therapeutics^®, Generx^®,Cardionovo™, Tissue Repair™, Gene Activated Matrix™, GAM™, Excellagen^®, Excellarate™, Osteorate™, MedPodium^®, Appexium^®, Linée^®, Alena^®, Cerex^®, D-Sorb™, Neo-Energy^®, Neo-Carb Bloc^®, Neo-Chill^™, and Nutra-Apps^® are trademarks of Cardium Therapeutics, Inc. or Tissue Repair Company.

GlobalWise (GWIV) Announces New Channel Sales Partnership With RJ Young

COLUMBUS, OH — (Marketwire) — 08/01/12 — GlobalWise Investments, Inc. (OTCBB: GWIV) (OTCQB: GWIV) (www.GlobalWiseInvestments.com) and its wholly owned subsidiary Intellinetics, Inc., a leading-edge technology company focused on the design, implementation and management of cloud-based Enterprise Content Management (“ECM”) systems in both the public and private sectors, today announce a new Channel Sales Partnership has been signed with RJ Young.

Since 1955, RJ Young has provided businesses across the Southeast with the highest quality office equipment and innovative document solutions — all backed by award-winning service. Today, RJ Young is the fifth largest independent dealer of its kind and has been recognized by Office Dealer magazine as one of the country’s 50 Best Office Equipment Dealers. RJ Young prides itself in partnering with the best copier and software providers in the world and saw the power of the Intellivue™ cloud-based ECM software from GlobalWise as the perfect complement to their managed print copier services for the small-sized to mid-sized client.

“RJ Young is a dominant force in the markets they serve for providing exceptional office equipment hardware and software solutions,” said William. J. “BJ” Santiago, CEO of GlobalWise. “With RJ Young on the team, we instantly gain access to an extensive sales force and client base throughout the Midwest. Their managed print solution powered by the Intellivue™ software portfolio will be a great value-added sales tool to not only sell more copiers, but also provide a complete document management solution which historically was too expensive for clients of this size.”

“The agreement with RJ Young also represents a new method for GlobalWise to find the right partners with the right approach to selling ECM services,” concluded Mr. Santiago. “The integration of the Intellivue™ software into the copier and multi-function printer eco-system provides a new revenue source for a ‘Per Click Charge’ to scan, archive, index and inventory documents in addition to the traditional per page charged for copies in color or black and white. This is a great addition to RJ Young’s product line-up, provides a fantastic value-added service for their clients and gives GlobalWise access to a strategic sales force and client base to work with.”

About GlobalWise Investments, Inc.

GlobalWise Investments, Inc., via its wholly owned subsidiary Intellinetics, Inc., is a Columbus, Ohio based Enterprise Content Management (ECM) pioneer with industry-leading software that delivers cloud ECM based solutions on-demand. The Company’s flagship platform, Intellivue™, represents a new industry benchmark and game-changing solution by enabling clients to access and manage the content of every scanned document, file, spreadsheet, email, photo, audio file or video tape — virtually anything that can be digitized — in their enterprise from any PC, laptop, tablet or smartphone from anywhere in the world.

For additional information, please visit the Company’s corporate website: www.GlobalWiseInvestments.com

This press release may contain “forward-looking statements.” Expressions of future goals and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements may include, without limitation, statements about our market opportunity, strategies, competition, expected activities and expenditures as we pursue our business plan. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot predict the effect that market conditions, customer acceptance of products, regulatory issues, competitive factors, or other business circumstances and factors described in our filings with the Securities and Exchange Commission may have on our results. The company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this press release.

GlobalWise Investments, Inc.
Columbus, Ohio
www.GlobalWiseInvestments.com
614-388-8909
Contact@GlobalWiseInvestments.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975